After being fired, I became the light of medicine

Chapter 74 Dean Zhou: It’s up to you now!

The news that Tsingshan Pharmaceutical's new drug code-named "QS-001" has entered the second phase of clinical trials has also spread to Baidu Tieba - Hepatitis B Bar.

The Hepatitis B Forum can be said to be the forum with the largest number of active patients in the entire forum.

The vast majority of patients here have been suffering from hepatitis B for ten or twenty years, and a very small number have even been suffering for thirty years.

Just as they said, they have already experienced dozens of drugs for treating hepatitis B over the years and have heard of various new drugs from countless pharmaceutical companies.

Even the country has proposed to cure hepatitis B since 2010, but fifteen years have passed and hepatitis B is still there.

Therefore, even if the country restarts the "Starlight Project" again, and even if new drugs are added to the "Starlight Project" one after another, the enthusiasm of patients in the entire forum for the "Starlight Project" is still very low.

Even cold.

Huang Yi is a small moderator of the Hepatitis B Forum. Although the discussion in the forum is not very popular, he will still take the time to post the latest information of various pharmaceutical companies on the forum as soon as there is any news.

He has always believed that as long as there are pharmaceutical companies developing hepatitis B drugs, there is still hope for hepatitis B patients.

But as usual, after he posted the post [Qingshan Pharmaceutical's latest drug "QS-001" officially entered the second phase of clinical trials], although the concept of "cytotoxicity" proposed by this drug is very novel, it took an hour to wait.
Obviously, there are hundreds of views on the post, but apart from advertisements from movie watchers and robots, there are no replies to the post.

This is indifference that can be felt personally.

"Hey!"

Huang Yi sighed helplessly.

……

The indifference of the Hepatitis B Forum seemed to have spread to the Phase II clinical recruitment of "Ekofovir". After Zhang Yang increased the trial subsidy to 20,000 yuan, it did attract many patients to come for consultation.

However, out of fear of cytotoxicity and hepatotoxicity, after a week, only five patients actually signed the informed consent form and were willing to participate in the trial.

Zhang Yang frowned as he looked at the data in his hand. He had already started thinking about whether to increase the experimental subsidy.

Considering the current pace of recruiting five people a week, this speed is too slow.

But while he was thinking about it,
Before he got anxious, Director Zhou of the Third People's Hospital of Chengdu became anxious first.

"Zhang Yang, he didn't even tell me when he had troubles. How mean!"

Dean Zhou slammed the table. One week after the Phase II clinical trial of Qingshan Pharmaceutical's "Ekofovir" was underway, he finally learned from Director Feng Gang about Qingshan Pharmaceutical's current predicament.

After a moment, he looked at the surprised Feng Gang and ordered:
"Director Feng, fortunately you reminded me in time. I will immediately notify all the doctors and nurses in the infectious disease department to hold a meeting."

Gave an order,
At five o'clock in the afternoon, President Zhou personally came to the meeting room of the infectious disease department of the inpatient department.

"To make a long story short, recently our well-known domestic pharmaceutical company, Qingshan Pharmaceutical, has launched a phase II clinical trial of a new hepatitis B cure drug 'QS-001' in our hospital. I'm sure everyone knows about this, right?"

Everyone nodded slightly.

With the launch of the national "Starlight Project", although the infectious disease department of the Third People's Hospital is not outstanding, it has received clinical trial tasks for two or three new drugs.

but,

In fact, Deputy Director Feng Gang had previously privately recommended this new drug, hoping that suitable hepatitis B patients would be given priority to participate in the trial of this new drug.

Unexpectedly, Dean Zhou personally brought up this matter at the meeting... Just as everyone was thinking about it, Dean Zhou continued:

"Since everyone knows this, why is it that after a week, Qingshan Pharmaceutical has even increased the trial subsidy by 20,000 yuan, but why are there still only five patients participating?"

After the words fell, everyone was stunned, even Chen Wen, the director of the infectious disease department, couldn't help but flash a hint of surprise.

Why is Dean Zhou suddenly so concerned about the development progress of a new drug?

As for why the development of Tsingshan Pharmaceutical's new drug is so slow, everyone knows it well. Tsingshan Pharmaceutical's "QS-001" is cytotoxic and patients have a strong resistance to it, which makes it very difficult!

At this moment, Dean Zhou's voice sounded again.

"I know this new drug is cytotoxic, but... we are all professional doctors. If the ethics committee allows this new drug to enter Phase II clinical trials, it means that the toxicity is controllable. The risk labeling is just to give patients the right to know!"

"Moreover, the purpose of cytotoxicity is to kill the hepatitis B virus, which means it is possible to cure hepatitis B. I believe that if I explain it well, there will definitely be hepatitis B patients willing to try it!"

At this point, he coughed heavily:
"I won't say more. I just want to make a request. Director Chen and the head nurse, please take note of it."

Director Chen Wen and the head nurse sat up straight instantly.

"From today on, all hepatitis B patients, whether inpatients or outpatients, must be recommended to participate in the trial of this new drug. In short, we fully support the Phase II clinical trial of 'QS-001' of Qingshan Pharmaceutical."

"Of course, we don't let you work for nothing. The finance department should keep a note that if a patient participates in the trial, the department's overall performance bonus will be increased by 1,000 yuan, which will be paid out the following month."

The conference room suddenly fell silent. Just three seconds later, the quiet conference room suddenly became a heated discussion!
Dean Zhou looked at the doctors and nurses in the audience who were very enthusiastic and a smile appeared on his face.

Thinking back to the time when Zhang Yang kept his promise and reached an agreement with himself despite the requests from many well-known hospitals, he felt that he was now repaying Zhang Yang for the favor.

"Zhang Yang, I told you from the beginning that I'm determined to be your friend!"

"Now, I have done my best, and now it's up to you!"

With the strong support of Director Zhou, doctors and nurses from the entire department gained an in-depth understanding of "Ekofovir" that afternoon.

This understanding revealed that
Yes, "Afovir" is indeed cytotoxic,
But as President Zhou said, since it has entered the Phase II clinical trial, it proves that the toxicity is controllable, and the reason for the cytotoxicity is to kill the hepatitis B virus.

As to whether hepatitis B can be cured, everyone is hesitant. After all, is there any medicine that can cure hepatitis B at present?
The next morning, a young patient appeared in the sight of department director Chen Wen.

Xu Bo, male, 32 years old, born in 1992.

Hepatitis B is different from other departments. As a chronic infectious disease, once hepatitis B patients take antiviral drugs, they need to take long-term medication and undergo regular check-ups.

Generally, hepatitis B patients need to undergo a follow-up examination every three months or at most six months, so most patients will choose a fixed doctor for long-term treatment.

The reason is very simple. Doctors who follow up on their patients for a long time often have a more comprehensive understanding of their conditions.

Xu Bo is a long-term patient of Director Chen Wen.

Two years ago, Xu Bo first realized the harm caused by hepatitis B and began to formally receive regular antiviral treatment.

After taking the medication for a year, he finally decided to try interferon.

(End of this chapter)